Nothing Special   »   [go: up one dir, main page]

JO3112B1 - تركيبة دوائية سريعة التحلل - Google Patents

تركيبة دوائية سريعة التحلل

Info

Publication number
JO3112B1
JO3112B1 JOP/2011/0100A JOP20110100A JO3112B1 JO 3112 B1 JO3112 B1 JO 3112B1 JO P20110100 A JOP20110100 A JO P20110100A JO 3112 B1 JO3112 B1 JO 3112B1
Authority
JO
Jordan
Prior art keywords
pharmaceutical composition
fast dissolving
dissolving pharmaceutical
matrix network
open matrix
Prior art date
Application number
JOP/2011/0100A
Other languages
English (en)
Inventor
Gunjikar Tejas
Ahuja Varinder
Wannerberger Kristin
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3112B1 publication Critical patent/JO3112B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/50Polysaccharides, gums
    • A23V2250/502Gums
    • A23V2250/5062Inulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير تركيبة صيدلانية تشتمل على شبكة مصفوفة مفتوحة تحمل المكون النشط صيدلانياً، حيث تشتمل شبكة المصفوفة المفتوحة على إنولين.
JOP/2011/0100A 2010-03-29 2011-03-22 تركيبة دوائية سريعة التحلل JO3112B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN742DE2010 2010-03-29

Publications (1)

Publication Number Publication Date
JO3112B1 true JO3112B1 (ar) 2017-09-20

Family

ID=54241475

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0100A JO3112B1 (ar) 2010-03-29 2011-03-22 تركيبة دوائية سريعة التحلل

Country Status (24)

Country Link
US (2) US10086078B2 (ar)
EP (1) EP2552403B1 (ar)
JP (1) JP5907945B2 (ar)
KR (1) KR101725173B1 (ar)
CN (1) CN102821755A (ar)
AR (1) AR080736A1 (ar)
AU (1) AU2011234636B2 (ar)
BR (1) BR112012024428A2 (ar)
CA (1) CA2793405A1 (ar)
DK (1) DK2552403T3 (ar)
ES (1) ES2553568T3 (ar)
HK (1) HK1181649A1 (ar)
HU (1) HUE026213T2 (ar)
IL (1) IL222086A (ar)
JO (1) JO3112B1 (ar)
MX (1) MX2012011204A (ar)
NZ (1) NZ602441A (ar)
PL (1) PL2552403T3 (ar)
PT (1) PT2552403E (ar)
RU (1) RU2566270C2 (ar)
SA (1) SA111320317B1 (ar)
TW (1) TWI513477B (ar)
WO (1) WO2011120903A2 (ar)
ZA (1) ZA201207176B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3254676T3 (pl) 2009-10-30 2019-06-28 Ix Biopharma Ltd Szybko rozpuszczająca się stała postać dawkowana
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
CA2848785A1 (en) * 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
CN106456535B (zh) * 2014-04-25 2020-07-03 R.P.谢勒技术有限公司 稳定的孟鲁司特溶液
EP3568124A1 (en) 2017-01-11 2019-11-20 Ferring B.V. A fast disintegrating pharmaceutical composition
CN111904936B (zh) * 2020-08-28 2022-07-19 开封康诺药业有限公司 一种法莫替丁冻干粉针剂
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA251629A (en) 1925-07-14 T. Hanna William Coal cutting knife
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4260602A (en) 1977-08-16 1981-04-07 Burroughs Wellcome Co. Hapten polysaccharide conjugate medicaments and method of use
CN1053808C (zh) 1993-04-24 2000-06-28 章修纲 尼非地平控释剂型
EP0879600A1 (en) 1997-05-20 1998-11-25 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Fructan containing composition for the prevention and treatment of colon cancer
EP0958825A1 (en) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
WO2000025754A2 (en) 1998-11-04 2000-05-11 Mcneil-Ppc, Inc. Solid oral dosage forms containing alginic acid and famotidine
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
NL1012300C2 (nl) * 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
EP1202716A1 (en) * 1999-08-17 2002-05-08 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
CN1556712A (zh) 2000-07-13 2004-12-22 ��һ��������ҩ��ʽ���� 含dds化合物的药用组合物
IT1319664B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di antibatterici chinolonici con polimeri polisaccaridicinaturali.
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
AU2003240759B2 (en) 2002-04-03 2008-02-14 Solvay Pharmaceuticals B.V. Stabilized natural cannabinoid formulation
BR0309819A (pt) 2002-05-07 2005-03-01 Ferring Bv Formulações farmacêuticas
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AU2002314112A1 (en) * 2002-05-27 2003-12-12 Istituto Biochimico Pavese Pharma S.P.A Dietary supplements from wine vinasses and relevant production process
US20040096569A1 (en) 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
JP4688787B2 (ja) 2003-02-28 2011-05-25 アルカベロ アクチェセルスカプ 糖類マトリックスを有する剤形
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
ES2300546T3 (es) 2003-09-05 2008-06-16 Myung-Jun Chung Polvo de bacterias del acido lactico doblemente recubiertas usando proteina y polisacarido y metodo de preparacion del mismo y forma farmaceutica del mismo.
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科(北京)研究院有限公司 一种口腔速溶制剂及其生产方法
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US20060088593A1 (en) 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
CN100339081C (zh) * 2004-11-10 2007-09-26 范敏华 一种氯雷他定口腔崩解片剂的制备方法
CN101102748A (zh) * 2004-12-23 2008-01-09 麦克内尔-Ppc股份有限公司 具有感觉提示剂的在口中分裂的药物组合物
US20070042023A1 (en) 2005-08-22 2007-02-22 National Starch And Chemical Investment Holding Corporation Dissolvable film
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
TW200817049A (en) 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
EP2129385A2 (en) 2007-03-27 2009-12-09 The Procter & Gamble Methods and kits for administering probiotics
JP5269894B2 (ja) 2007-06-27 2013-08-21 ハンミ ファーム. シーオー., エルティーディー. 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置
KR100930427B1 (ko) 2008-01-25 2009-12-08 정명준 3중 코팅 유산균의 제조방법 및 나노 입자 코팅 방법, 그방법으로 제조된 3중 코팅 유산균 및 이를 포함하는 제품
US8623401B2 (en) 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
EP2318511B1 (en) * 2008-08-28 2017-08-02 Chr. Hansen A/S Bacterial composition
US8946153B2 (en) 2010-03-29 2015-02-03 Ferring B.V. Fast dissolving pharmaceutical composition
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
CA2848785A1 (en) 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
US20150306170A1 (en) 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release

Also Published As

Publication number Publication date
SA111320317B1 (ar) 2015-05-11
CN102821755A (zh) 2012-12-12
KR20130008588A (ko) 2013-01-22
ZA201207176B (en) 2013-05-29
HUE026213T2 (en) 2016-05-30
AU2011234636A1 (en) 2012-10-11
AR080736A1 (es) 2012-05-02
JP5907945B2 (ja) 2016-04-26
MX2012011204A (es) 2012-11-23
US10086078B2 (en) 2018-10-02
TW201138830A (en) 2011-11-16
EP2552403B1 (en) 2015-09-09
US20180369392A1 (en) 2018-12-27
BR112012024428A2 (pt) 2016-05-31
US20130123180A1 (en) 2013-05-16
US10512695B2 (en) 2019-12-24
ES2553568T3 (es) 2015-12-10
NZ602441A (en) 2014-01-31
KR101725173B1 (ko) 2017-04-10
AU2011234636B2 (en) 2015-01-15
JP2013523676A (ja) 2013-06-17
RU2012141141A (ru) 2014-05-10
PL2552403T3 (pl) 2016-01-29
EP2552403A2 (en) 2013-02-06
IL222086A (en) 2017-01-31
HK1181649A1 (en) 2013-11-15
RU2566270C2 (ru) 2015-10-20
WO2011120903A3 (en) 2012-05-03
CA2793405A1 (en) 2011-10-06
DK2552403T3 (en) 2015-10-05
WO2011120903A2 (en) 2011-10-06
PT2552403E (pt) 2015-10-30
TWI513477B (zh) 2015-12-21

Similar Documents

Publication Publication Date Title
MX341200B (es) Composicion farmaceutica de disolucion rapida.
SA112330855B1 (ar) تركيبة صيدلانية سريعة الذوبان
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
EP3216448B8 (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
LT2808325T (lt) Pakeistieji azolai, antivirusinis aktyvus ingredientas, farmacinė kompozicija, jų gavimo ir panaudojimo būdas
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
IN2015DN03984A (ar)
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EP2394986A4 (en) DERIVATIVES OF 3 AMINOXALYLAMINOBENZAMIDE AND INSECTICIDE AND MITICIDE AGENTS CONTAINING SAME AS ACTIVE INGREDIENT
TW200942524A (en) Novel aminomethyl benzene derivatives
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
TW200942530A (en) Pyridine compounds
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
MY152951A (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
MX339306B (es) Agente anti-fungico.
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
EP2476420B8 (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same
WO2011156045A3 (en) Tablet formulation of ezatiostat
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
WO2010104485A3 (en) Valsartan formulations